MedPath
NMPA Approval

Ibrutinib Capsules

国药准字H20249566

December 1, 2024

Drug Information

伊布替尼胶囊

胶囊剂

140mg

化学药品

December 1, 2024

Company Information

Applicant Company

山东省淄博市临淄区宏达路17号

Manufacturing Company

北京市北京经济技术开发区科创东六街97号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.